GSK Lapatinib Breast Cancer Development Shifts To Front-Line Setting
GlaxoSmithKline will shift its plans for the breast cancer agent lapatinib to focus on front-line use rather than refractory patients, the company said May 15
You may also be interested in...
GlaxoSmithKline's strategy of building its oncology business is paying off with a range of new chemical entities entering Phase III development within the next year for cancer-related indications, executives said during an oncology R&D update in New York
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011